Psychedelic API Market To Reach $6.1B By 2033 Boosted By LSD: New Analysis

February 10, 2023 · Benzinga

The psychedelic Active Pharmaceutical Ingredient (API) Market, currently estimated at $1.6 billion, is expected to rise at a CAGR of 13.2% over the next ten years and be worth $6.1 billion by the end of 2033.

That’s according to Persistence Market Research’s latest study, conducted by a team of experts in management, medicine and engineering.

“Increasing cGMP practices, growth in the pharmaceutical API manufacturing industry and increasing research on the impact of psychedelics on mental health are factors propelling the global market,” stated a Persistence Market Research analyst.

Past research located the worth of the global psychedelic market at $8.31 billion by 2028 and $12 billion by 2029.

The latest API report noted:

  • LSD APIs held 33.7% market share by product in 2022.
  • Novel synthetic compounds accounted for 42.2% share of the global psychedelic API market in 2022.
  • Synthetic sources held a share of 54.0% in the global market in 2022.
  • GMP-grade production held a market share of 97.8% in 2022.
  • By application, the research segment held a market share of 87.0% in 2022.
  • Around 33.3% of the global market share, by region, was accounted for by North America in 2022.

The study also presents a historical demand assessment of the period 2017-2022 and projections for the next ten years, through sections including products (API-grade psilocybin, DMT, LSD, MDMA, and ketamine), the API compound (active plant components, novel synthetic compounds, metabolites, isotopically labeled standards), source (natural, synthetic, bio-synthetic), grade (GMP, non-GMP), application (clinical, research), and considers key geographical regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa). (Full Story)

In categories:Business Psychedelics
Next Post

First NYS adult-use cannabis dispensary in Upstate NY, Southern Tier opens for business

BINGHAMTON, N.Y. — The first adult-use cannabis dispensary north of New York City opened for business Friday on Court Street in Binghamton. It's no short drive for Western New Yorkers, at seven hours round-trip, but it is half the distance…
Previous Post

Canopy Growth closing Tweed’s Smiths Falls facility, laying off 800 workers

The layoffs will represent 35 per cent of the company’s workforce. Forty per cent of the cuts will be immediate while the rest will take place over the course of the coming months. The former Hershey chocolate factory at 1 Hershey Drive…
Random Post

Feds And Marijuana Businesses Jointly Agree On Deadline Extension For Lawsuit Challenging Prohibition

The U.S. attorney general and a coalition of marijuana businesses represented by an influential law firm have jointly agreed to request a deadline extension for the filing of initial briefs in a much-anticipated lawsuit against the federal government that seeks…
Random Post

Montana’s Legal Marijuana Sales Hit Record $28.7 Million in August

Purchases of adult-use cannabis in Montana hit a monthly record in August, according to newly released sales numbers from the state’s Cannabis Control Division. Medical marijuana receipts for the month, meanwhile, were at their lowest since adult-use stores opened in…
Random Post

No New Cannabis Business Licenses in San Francisco Until 2028

Estimates say the illicit market accounts for roughly 60% of San Francisco cannabis business. San Francisco has apparently settled on a deal for a temporary ban on new marijuana business permits in the city, after an initial proposal to indefinitely prohibit new…
Random Post

John Oliver’s Makes The Case For Psychedelic Assisted Therapy On ‘Last Week Tonight’

John Oliver is back on “Last Week Tonight” and is once again taking a deep dive into a very intriguing topic: the potential benefits of psychedelic assisted therapy. The show, which aired on Sunday, delves into the history of psychedelics and its potential…